ResearcherActive in the last 2 years

David Killock

ORCID-verified (high confidence)As of 14 November 2026

Matched on ORCID iD 0000-0002-3267-8284; OpenAlex author ID A5016958680.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 2 (first author 2, last author 0)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 0

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer. First author DOI 10.1038/s41571-026-01162-x ↗
Pancreatic cancer: A problem quartered--new subtypes, new solutions? First author DOI 10.1038/nrclinonc.2016.39 ↗

Closest collaborators

No collaborators recorded.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.